Hu Q, Shi Y, Wang H, Bing L, Xu Z
Exp Hematol Oncol. 2025; 14(1):37.
PMID: 40087690
DOI: 10.1186/s40164-025-00627-6.
Roussot N, Kaderbhai C, Ghiringhelli F
Cancers (Basel). 2025; 17(5).
PMID: 40075753
PMC: 11898530.
DOI: 10.3390/cancers17050906.
Liu L, Wu P, Wang B, Dong J, Zhang C, Liu W
Cancer Immunol Immunother. 2025; 74(4):134.
PMID: 40035834
PMC: 11880484.
DOI: 10.1007/s00262-025-03985-6.
Jeppesen D, Sanchez Z, Kelley N, Hayes J, Ambroise J, Koory E
Nat Cell Biol. 2025; 27(3):438-448.
PMID: 39984653
PMC: 11906356.
DOI: 10.1038/s41556-025-01621-0.
Clegg J, Mnich M, Carignano A, Cova G, Tavarini S, Sammicheli C
Front Immunol. 2025; 15:1500696.
PMID: 39981298
PMC: 11840346.
DOI: 10.3389/fimmu.2024.1500696.
Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802).
Bando H, Kumagai S, Kotani D, Mishima S, Irie T, Itahashi K
Nat Cancer. 2025; .
PMID: 39972105
DOI: 10.1038/s43018-025-00918-1.
TIGIT expression in extrahepatic cholangiocarcinoma and its impact on CD8 + T cell exhaustion: implications for immunotherapy.
Tang T, Wang W, Gan L, Bai J, Tan D, Jiang Y
Cell Death Dis. 2025; 16(1):90.
PMID: 39939322
PMC: 11822069.
DOI: 10.1038/s41419-025-07388-4.
The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies.
Vijayanathan Y, Ho I
Int J Mol Sci. 2025; 26(2).
PMID: 39859381
PMC: 11765942.
DOI: 10.3390/ijms26020669.
New insight in immunotherapy and combine therapy in colorectal cancer.
Ji K, Jia H, Liu Z, Yu G, Wen R, Zhang T
Front Cell Dev Biol. 2025; 12():1453630.
PMID: 39839672
PMC: 11747282.
DOI: 10.3389/fcell.2024.1453630.
Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?.
Cui H, Elkord E
Vaccines (Basel). 2025; 12(12.
PMID: 39771968
PMC: 11679306.
DOI: 10.3390/vaccines12121306.
Enhancement of Human Immunodeficiency Virus-Specific CD8 T Cell Responses with TIGIT Blockade Involves Trogocytosis.
Ghasemi N, Holder K, Ings D, Grant M
Pathogens. 2025; 13(12.
PMID: 39770396
PMC: 11679564.
DOI: 10.3390/pathogens13121137.
Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.
Hosseininejad-Chafi M, Eftekhari Z, Oghalaie A, Behdani M, Sotoudeh N, Kazemi-Lomedasht F
Med Oncol. 2024; 42(1):36.
PMID: 39719469
DOI: 10.1007/s12032-024-02588-y.
Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes.
Franzese O
Int J Mol Sci. 2024; 25(23).
PMID: 39684559
PMC: 11641238.
DOI: 10.3390/ijms252312848.
The emerging role of Fusobacteria in carcinogenesis.
Gibbs R, Chambers A, Hill D
Eur J Clin Invest. 2024; 54 Suppl 2:e14353.
PMID: 39674881
PMC: 11646295.
DOI: 10.1111/eci.14353.
Single-cell analysis reveals expanded CD8 T cells in CSF and shared peripheral clones in sporadic amyotrophic lateral sclerosis.
Kim H, Ban J, Kang J, Im H, Ko S, Sung J
Brain Commun. 2024; 6(6):fcae428.
PMID: 39659975
PMC: 11631212.
DOI: 10.1093/braincomms/fcae428.
Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer.
Connor A, Lyons P, Kilgallon A, Simpson J, Perry A, Lysaght J
Heliyon. 2024; 10(20):e38888.
PMID: 39640610
PMC: 11620064.
DOI: 10.1016/j.heliyon.2024.e38888.
Exploring the role of Fusobacterium nucleatum in colorectal cancer: implications for tumor proliferation and chemoresistance.
Dadgar-Zankbar L, Elahi Z, Shariati A, Khaledi A, Razavi S, Khoshbayan A
Cell Commun Signal. 2024; 22(1):547.
PMID: 39548531
PMC: 11566256.
DOI: 10.1186/s12964-024-01909-y.
A Novel Prognostic Nomogram Based on TIGIT and NKG2A Can Predict Relapse-Free Survival of Hepatocellular Carcinoma After Hepatectomy.
Wang J, Cao Y, Tian Y, Dai C, Jin T, Xu F
Cancer Med. 2024; 13(22):e70419.
PMID: 39540362
PMC: 11561519.
DOI: 10.1002/cam4.70419.
Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors.
Malhotra J, Huang A, Amini A, Lee P
Cancers (Basel). 2024; 16(21).
PMID: 39518043
PMC: 11545025.
DOI: 10.3390/cancers16213603.
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.
Chen S, Zhu H, Jounaidi Y
Signal Transduct Target Ther. 2024; 9(1):302.
PMID: 39511139
PMC: 11544004.
DOI: 10.1038/s41392-024-02005-w.